{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T01:08:13Z","timestamp":1773018493350,"version":"3.50.1"},"reference-count":35,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"unspecified","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR302258"],"award-info":[{"award-number":["NIHR302258"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003185","name":"National Psoriasis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003185","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,9,25]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Targeted biologic therapies have transformed outcomes for individuals with psoriasis, a common immune-mediated inflammatory skin disease. The widespread use of these highly effective treatments has led to a growing number of individuals with clear or nearly clear skin remaining on continuous, long-term treatment. Personalised strategies to minimise drug exposure may sustain long-term disease control while reducing treatment burden, associated risks and healthcare costs. This study aims to evaluate the feasibility of a definitive pragmatic effectiveness trial of two personalised dose minimisation strategies compared with continuous treatment (standard care) in adults with well-controlled psoriasis receiving the exemplar biologic risankizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This is a multicentre, assessor-blind, parallel group, open-label randomised controlled feasibility trial in the UK, evaluating two personalised biologic dose minimisation strategies for psoriasis. 90 adults with both physician-assessed and patient-assessed clear or nearly clear skin on risankizumab monotherapy for \u226512 months will be randomised in a 1:1:1 ratio to (1) patient-led \u2018as-needed\u2019 treatment, where risankizumab is administered at the first sign of self-assessed psoriasis recurrence, (2) therapeutic drug monitoring-guided treatment, with personalised dosing intervals determined using a pharmacokinetic model or (3) continuous treatment as per standard care, for 12 months. Participants will be invited to submit self-reported outcomes and self-taken photographs every 3 months using a bespoke remote monitoring system (mySkin app) and will attend an in-person assessment at 12 months. They may also request additional patient-initiated follow-up appointments during the trial if needed. The primary outcome is the practicality and acceptability of the two personalised biologic dose minimisation strategies, assessed as a composite measure including recruitment and retention rates, adherence to the assigned strategies and acceptability to both patients and clinicians. The feasibility of collecting healthcare cost and resource utilisation data will also be evaluated to inform a future cost-effectiveness analysis. A nested qualitative study, involving semistructured interviews with patients and clinicians, will explore perspectives on the personalised biologic dose minimisation strategies. These findings will inform the design of a future definitive trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study received ethical approval from the Seasonal Research Ethics Committee (reference 24\/LO\/0089). Results will be disseminated through scientific conferences, peer-reviewed publications and patient\/public engagement events. Lay summaries and infographics will be codeveloped with patient partners to ensure the findings are accessible for the wider public.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"isrctn\" xlink:href=\"ISRCTN17922845\">ISRCTN17922845<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-106635","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:50:44Z","timestamp":1760093444000},"page":"e106635","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["PLAN-psoriasis: protocol for a randomised controlled feasibility trial comparing patient-led \u2018as-needed\u2019 treatment and therapeutic drug monitoring-guided treatment to continuous treatment for adults with clear or almost clear skin on risankizumab monotherapy for psoriasis"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"isrctn17922845","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8983-0355","authenticated-orcid":false,"given":"Weiyu","family":"Ye","sequence":"first","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust & King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kingsley","family":"Powell","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust & King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niamh","family":"Dooley","sequence":"additional","affiliation":[{"name":"Social, Genetic and Developmental Psychiatry Centre, King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte M","family":"Thomas","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust & King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bola","family":"Coker","sequence":"additional","affiliation":[{"name":"Research and Development, Guy's and St Thomas\u2019 NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"McAteer","sequence":"additional","affiliation":[{"name":"Psoriasis Association, Northampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica Ruoheng","family":"Wei","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust & King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5076-0206","authenticated-orcid":false,"given":"Wei Ren","family":"Tan","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust & King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Baudry","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust & King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tejus","family":"Dasandi","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust & King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jade","family":"Pizzato","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust & King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8098-9220","authenticated-orcid":false,"given":"Tracey H","family":"Sach","sequence":"additional","affiliation":[{"name":"School of Primary Care, Population Sciences and Medical Education, University of Southampton, Southampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Gregory","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust & King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7041-459X","authenticated-orcid":false,"given":"Zijing","family":"Yang","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew E","family":"Pink","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust & King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard T","family":"Woolf","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust & King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard B","family":"Warren","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Northern Care Alliance NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Weinman","sequence":"additional","affiliation":[{"name":"Centre for Adherence Research and Education, King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan N","family":"Barker","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust & King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7612-1605","authenticated-orcid":false,"given":"Sarah","family":"Chapman","sequence":"additional","affiliation":[{"name":"Centre for Adherence Research and Education, King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F","family":"Standing","sequence":"additional","affiliation":[{"name":"Infection, Immunity and Inflammation Research & Teaching Department, UCL Great Ormond Street Institute of Child Health, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Norton","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine H","family":"Smith","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust & King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satveer","family":"K Mahil","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust & King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"2025120415064830000_15.10.e106635.1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339"},{"key":"2025120415064830000_15.10.e106635.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6"},{"key":"2025120415064830000_15.10.e106635.3","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jaad.2023.07.1024","article-title":"Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up","volume":"89","author":"Papp","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2025120415064830000_15.10.e106635.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512711"},{"key":"2025120415064830000_15.10.e106635.5","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"7","author":"Sbidian","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"2025120415064830000_15.10.e106635.6","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamadermatol.2021.2599","article-title":"Association Between Biologics Use and Risk of Serious Infection in Patients With Psoriasis","volume":"157","author":"Penso","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2025120415064830000_15.10.e106635.7","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15830"},{"key":"2025120415064830000_15.10.e106635.8","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2012.660520"},{"key":"2025120415064830000_15.10.e106635.9","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaad.2020.08.026","article-title":"The risk of respiratory tract infections and interstitial lung disease with interleukin 12\/23 and interleukin 23 antagonists in patients with autoimmune diseases: A systematic review and meta-analysis","volume":"84","author":"Akiyama","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2025120415064830000_15.10.e106635.10","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/bjd\/ljac144","article-title":"Nonadherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey","volume":"188","author":"Quirke-McFarlane","year":"2023","journal-title":"Br J Dermatol"},{"key":"2025120415064830000_15.10.e106635.11","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12118"},{"key":"2025120415064830000_15.10.e106635.12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00403-021-02273-4","article-title":"Attitudes and behaviour regarding dose reduction of biologics for psoriasis: a survey among dermatologists worldwide","volume":"314","author":"van Muijen","year":"2022","journal-title":"Arch Dermatol Res"},{"key":"2025120415064830000_15.10.e106635.13","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2025120415064830000_15.10.e106635.14","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/jdv.16803","article-title":"Intermittent use of biologic agents for the treatment of psoriasis in adults","volume":"35","author":"Al-Hammadi","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025120415064830000_15.10.e106635.15","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1016\/j.jid.2019.05.016","article-title":"Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study","volume":"139","author":"Gordon","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2025120415064830000_15.10.e106635.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.10139.x"},{"key":"2025120415064830000_15.10.e106635.17","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/jdv.14163","article-title":"Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis","volume":"31","author":"Blauvelt","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025120415064830000_15.10.e106635.18","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00679-y"},{"key":"2025120415064830000_15.10.e106635.19","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamadermatol.2019.4897","article-title":"Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis: A Randomized Clinical Trial","volume":"156","author":"Atalay","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2025120415064830000_15.10.e106635.20","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bjd.18143","article-title":"Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025120415064830000_15.10.e106635.21","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1111\/bjd.15722","article-title":"Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR)","volume":"177","author":"Blauvelt","year":"2017","journal-title":"Br J Dermatol"},{"key":"2025120415064830000_15.10.e106635.22","unstructured":"National Institute for Health and Care Excellence . Psoriasis: assessment and management, Available: https:\/\/www.nice.org.uk\/guidance\/cg153"},{"key":"2025120415064830000_15.10.e106635.23","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/bjd\/ljae068","article-title":"Acceptability of \u201cas needed\u201d biologic therapy in psoriasis: insights from a multistakeholder mixed-methods study","volume":"191","author":"Gleeson","year":"2024","journal-title":"Br J Dermatol"},{"key":"2025120415064830000_15.10.e106635.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.07.028"},{"key":"2025120415064830000_15.10.e106635.25","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/jcph.1268","article-title":"Exposure-Response Modeling to Characterize the Relationship Between Ixekizumab Serum Drug Concentrations and Efficacy Responses at Week 12 in Patients With Moderate to Severe Plaque Psoriasis","volume":"58","author":"Chigutsa","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"2025120415064830000_15.10.e106635.26","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/cpt.1594","article-title":"Exposure\u2013Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients","volume":"107","author":"Khatri","year":"2020","journal-title":"Clin Pharma and Therapeutics"},{"key":"2025120415064830000_15.10.e106635.27","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jid.2025.01.031","article-title":"Personalizing Biologic Therapy in Psoriasis: Development, Validation, and User Testing of a Precision-Dosing Dashboard","volume":"145","author":"Thomas","year":"2025","journal-title":"Journal of Investigative Dermatology"},{"key":"2025120415064830000_15.10.e106635.28","unstructured":"Research Inclusion Strategy 2022-2027 | NIHR, Available: https:\/\/www.nihr.ac.uk\/about-us\/who-we-are\/research-inclusion\/strategy-2022-27"},{"key":"2025120415064830000_15.10.e106635.29","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/jvc2.516","article-title":"A toolkit to facilitate skin research participation in underrepresented ethnic populations: A co\u2010designed, mixed methods refinement exercise","volume":"3","author":"Choy","year":"2024","journal-title":"JEADV Clinical Practice"},{"key":"2025120415064830000_15.10.e106635.30","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1001\/jamadermatol.2020.5844","article-title":"Association of Patient Mental Health Status With the Level of Agreement Between Patient and Physician Ratings of Psoriasis Severity","volume":"157","author":"Carr","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2025120415064830000_15.10.e106635.31","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-017-2031-8","article-title":"Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework","volume":"17","author":"Sekhon","year":"2017","journal-title":"BMC Health Serv Res"},{"key":"2025120415064830000_15.10.e106635.32","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.21316"},{"key":"2025120415064830000_15.10.e106635.33","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i5239","article-title":"CONSORT 2010 statement: extension to randomised pilot and feasibility trials","volume":"355","author":"Eldridge","year":"2016","journal-title":"BMJ"},{"key":"2025120415064830000_15.10.e106635.34","doi-asserted-by":"crossref","DOI":"10.2196\/11734","article-title":"RADAR-Base: Open Source Mobile Health Platform for Collecting, Monitoring, and Analyzing Data Using Sensors, Wearables, and Mobile Devices","volume":"7","author":"Ranjan","year":"2019","journal-title":"JMIR Mhealth Uhealth"},{"key":"2025120415064830000_15.10.e106635.35","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/bjd.18209","article-title":"The top 10 research priorities for psoriasis in the U.K.: results of a James Lind Alliance psoriasis Priority Setting Partnership","volume":"181","author":"Majeed-Ariss","year":"2019","journal-title":"Br J Dermatol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-106635","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T23:10:23Z","timestamp":1764889823000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-106635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,10]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/bmjopen-2025-106635"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-106635","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}